Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mevalonic acid is a small molecule organic compound classified as a hydroxy fatty acid. It is a key intermediate in the biosynthetic pathway known as the mevalonate pathway, which produces terpenes in plants and steroids in animals. Mevalonic acid is the primary precursor of isopentenyl pyrophosphate (IPP), which forms the basis for all terpenoids and sterols, including cholesterol. The production of mevalonic acid by 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) represents the rate-limiting step in cholesterol biosynthesis. Statin drugs lower cholesterol by inhibiting HMG-CoA reductase and thus reducing endogenous production of mevalonic acid[1][4][5]. Mevalonic acid itself has been studied experimentally for its effects on cholesterol metabolism and skin barrier function but is not an approved pharmaceutical drug[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mevalonic acid.